Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial.
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Durvalumab (Primary) ; Bevacizumab
- Indications Advanced breast cancer
- Focus Pharmacodynamics; Proof of concept
- 07 Jun 2017 Biomarkers information updated
- 23 Jun 2016 New trial record
- 13 Jun 2016 Status changed from recruiting to active, no longer recruiting.